EVALUATION OF CYP2B6 INDUCTION AND PREDICTION OF CLINICAL DRUG-DRUG INTERACTIONS

被引：0
|
作者：
Fahmi, Odette A. [1 ]
机构：
[1] Pfizer, Pharmacokinet & Drug Metab, Groton, CT 06340 USA
来源：
DRUG METABOLISM AND PHARMACOKINETICS | 2017年 / 32卷 / 01期
关键词：
D O I：
10.1016/j.dmpk.2016.10.083
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
S62
引用
收藏
页码：S18 / S18
页数：1
相关论文
共 50 条
  • [1] Evaluation of CYP2B6 Induction and Prediction of Clinical Drug-Drug Interactions: Considerations from the IQ Consortium Induction Working Group-An Industry Perspective
    Fahmi, Odette A.
    Shebley, Mohamad
    Palamanda, Jairam
    Sinz, Michael W.
    Ramsden, Diane
    Einolf, Heidi J.
    Chen, Liangfu
    Wang, Hongbing
    DRUG METABOLISM AND DISPOSITION, 2016, 44 (10) : 1720 - 1730
  • [2] Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of Lemborexant
    Landry, Ishani
    Aluri, Jagadeesh
    Nakai, Kenya
    Hall, Nancy
    Miyajima, Yukiko
    Ueno, Takashi
    Dayal, Satish
    Filippov, Gleb
    Lalovic, Bojan
    Moline, Margaret
    Reyderman, Larisa
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (06): : 681 - 690
  • [3] USE OF PBPK MODELING FOR DRUG-DRUG INTERACTIONS PREDICTION OF RIFAPENTINE ON OTHER DRUGS BY INDUCTION OF CYP3A4/5 AND CYP2B6
    Nicolas, Olivier
    Vermet, Helene
    Demers, Brigitte
    Boulenc, Xavier
    Sultan, Eric
    Donat, Francois
    Farenc, Christine
    DRUG METABOLISM AND PHARMACOKINETICS, 2018, 33 (01) : S49 - S49
  • [4] In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype
    Rekic, Dinko
    Roshammar, Daniel
    Mukonzo, Jackson
    Ashton, Michael
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (04) : 536 - 543
  • [5] A genetic algorithm-based approach for the prediction of metabolic drug-drug interactions involving CYP2C8 or CYP2B6
    Di Paolo, Veronica
    Ferrari, Francesco Maria
    Veronese, Davide
    Poggesi, Italo
    Quintieri, Luigi
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2024, 127
  • [6] Insights into CYP2B6-mediated drug-drug interactions
    Hedrich, William D.
    Hassan, Hazem E.
    Wang, Hongbing
    ACTA PHARMACEUTICA SINICA B, 2016, 6 (05) : 413 - 425
  • [7] Quantitative prediction of CYP3A induction-mediated drug-drug interactions in clinical practice
    Tsutsui, Haruka
    Kato, Motohiro
    Kuramoto, Shino
    Yoshinari, Kouichi
    DRUG METABOLISM AND PHARMACOKINETICS, 2024, 57
  • [8] Contribution of drug ionization to prediction of hepatic clearance and drug-drug interactions for CYP2D6
    Rougee, Luc R. A.
    Mohutsky, Michael A.
    Bedwell, David B.
    Ruterbories, Kenneth J.
    Hall, Stephen D.
    DRUG METABOLISM REVIEWS, 2016, 48 : 24 - 25
  • [9] EVALUATION OF CYP2B6 INDUCTION AND PREDICTION OF CLINICAL DDI USING PBPK MODELING.
    Ke, A.
    Barter, Z.
    Yeo, K. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S69 - S69
  • [10] Prediction of In Vivo Drug-Drug Interactions from In Vitro DataFactors Affecting Prototypic Drug-Drug Interactions Involving CYP2C9, CYP2D6 and CYP3A4
    Hayley S. Brown
    Aleksandra Galetin
    David Hallifax
    J. Brian Houston
    Clinical Pharmacokinetics, 2006, 45 : 1035 - 1050
12345